| 000 | 02347nam a2200193Ia 4500 | ||
|---|---|---|---|
| 008 | 250806s9999||||xx |||||||||||||| ||und|| | ||
| 020 | _a9780471752158 (cloth);0471752150 (cloth) | ||
| 060 |
_aQV 744 _b.A78 2007 |
||
| 245 | 4 |
_aThe art of drug synthesis / _cedited by Douglas S. Johnson, Jie Jack Li. |
|
| 260 |
_aHoboken, N.J. : _bWiley-Interscience, _cc2007. |
||
| 300 |
_axv, 276 p. : _bill. |
||
| 504 | _aIncludes bibliographical references and index. | ||
| 505 | _aThe role of medicinal chemistry in drug discovery / John A. Lowe III -- Process research: how much? how soon? / Neal G. Anderson -- Aromatase inhibitors for breast cancer: exemestane (aromasin), anastrozole (arimidex), and letrozole (femara) / Jie Jack Li -- Quinolone antibiotics: levofloxacin (levaquin), moxifloxacin (avelox), gemifloxacin (factive), and garenoxacin (T-3811) / Chris Limberakis -- Triazole antifungals: itraconazole (sporanox), fluconazole (diflucan), voriconazole (vfend), and fosfluconazole (prodif) / Andrew S. Bell -- Non-nucleoside HIV reverse transcriptase inhibitors / Arthur Harms -- Neuraminidase inhibitors for influenza: oseltamivir phosphate (tamiflu), and zanamivir (relenza) / Douglas S. Johnson and Jie Jack Li -- Peroxisome proliferator-activated receptor (PPAR) agonists for type 2 diabetes / Jin Li -- Angiotensin AT1 antagonists for hypertension / Larry Yet -- Leading ACE inhibitors for hypertension / Victor J. Cee and Edward J. Olhava -- Dihydropyridine calcium channel blockers for hypertension / Daniel P. Christen -- Second-generation HMG-CoA reductase inhibitors /Jeffrey A. Pfefferkorn -- Cholesterol absorption inhibitors: ezetimibe (zetia) / Stuart B. Rosenblum -- Dual selective serotonin and norepinephrine reuptake inhibitors (SSNRIs) for depression / Marta Pin??eiro-Nun??ez -- GABAA receptor agonists for insomnia: zolpidem (ambien), zaleplon (sonata), eszopiclone (estorra, lunesta), and indiplon / Peter R. Guzzo -- [alpha]2[delta] ligands: neurontin (gabapentin) and lyrica (pregabalin) / Po-Wai Yuen -- Approved treatments for attention deficit hyperactivity disorder: amphetamine (adderall), methylphenidate (ritalin), and atomoxetine (stratterra) / David L. Gray. | ||
| 650 | _aChemistry, Pharmaceutical | ||
| 650 | _aDrug Design | ||
| 700 | _aJohnson, Douglas S. | ||
| 700 | _aLi, Jie Jack. | ||
| 942 |
_bDIMC _cBK |
||
| 999 |
_c27936 _d27936 |
||